Integra LifeSciences (NASDAQ:IART) Stock Price Breaks Above Two Hundred Day Moving Average - Here's What Happened

Integra LifeSciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Integra LifeSciences shares rose 8.7% and moved above their 200-day moving average of $14.10, reaching $15.15 before last trading at $14.82.
  • Analyst views remain mixed: the consensus rating is “Reduce”, with an average price target of $16.12; two analysts rate the stock Buy, five Hold, and three Sell.
  • The company reported quarterly earnings of $0.59 per share, beating estimates of $0.56, while revenue of $411.18 million fell short of the $413.16 million forecast.
  • Five stocks to consider instead of Integra LifeSciences.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $14.10 and traded as high as $15.15. Integra LifeSciences shares last traded at $14.82, with a volume of 1,174,234 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on IART shares. Citigroup reiterated an "outperform" rating on shares of Integra LifeSciences in a research report on Thursday, October 22nd. Wells Fargo & Company set a $13.00 price target on Integra LifeSciences and gave the stock an "equal weight" rating in a research report on Thursday, October 22nd. BMO Capital Markets reissued a "market perform" rating and set a $14.00 target price (down from $15.00) on shares of Integra LifeSciences in a research note on Thursday, October 22nd. Zacks Research downgraded Integra LifeSciences from a "hold" rating to a "strong sell" rating in a research report on Monday, October 26th. Finally, Weiss Ratings raised shares of Integra LifeSciences from a "sell (e+)" rating to a "sell (d+)" rating in a research note on Monday, October 26th. Two analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Reduce" and an average price target of $16.12.

Check Out Our Latest Analysis on Integra LifeSciences

Integra LifeSciences Stock Up 8.7%

The firm's 50 day simple moving average is $14.67 and its 200-day simple moving average is $14.10. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 87.18, a P/E/G ratio of 0.53 and a beta of 1.28. The company has a debt-to-equity ratio of 1.67, a current ratio of 3.62 and a quick ratio of 2.21.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The life sciences company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.03. The company had revenue of $411.18 million during the quarter, compared to analysts' expectations of $413.16 million. Integra LifeSciences had a return on equity of 18.63% and a net margin of 0.79%. During the same quarter in the previous year, the business earned ($0.07) earnings per share. As a group, sell-side analysts anticipate that Integra LifeSciences Holdings Corporation will post 2.34 earnings per share for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the company. Inspire Investing LLC grew its stake in Integra LifeSciences by 5.2% in the 3rd quarter. Inspire Investing LLC now owns 39,168 shares of the life sciences company's stock valued at $638,000 after acquiring an additional 1,929 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in Integra LifeSciences by 1.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 152,837 shares of the life sciences company's stock valued at $2,488,000 after buying an additional 2,889 shares during the last quarter. Sequoia Financial Advisors LLC increased its position in Integra LifeSciences by 27.4% during the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company's stock worth $134,000 after buying an additional 3,059 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of Integra LifeSciences in the second quarter valued at $82,000. Finally, Integrated Wealth Concepts LLC purchased a new stake in Integra LifeSciences during the 2nd quarter worth about $84,000. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Holdings Corporation NASDAQ: IART is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra's neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Integra LifeSciences Right Now?

Before you consider Integra LifeSciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.

While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines